Monitoring cognitive functioning in multiple sclerosis will trigger anxiety in patients: Commentary.
作者信息
Morrow Sarah A, Hancock Laura
机构信息
Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
出版信息
Mult Scler. 2024 Sep;30(10):1256-1257. doi: 10.1177/13524585241261200. Epub 2024 Jun 16.
Abstract
摘要
相似文献
1
Monitoring cognitive functioning in multiple sclerosis will trigger anxiety in patients: Commentary.
Mult Scler. 2024 Sep;30(10):1256-1257. doi: 10.1177/13524585241261200. Epub 2024 Jun 16.
2
Monitoring cognitive functioning in MS will trigger anxiety in patients: No.
Mult Scler. 2024 Sep;30(10):1254-1256. doi: 10.1177/13524585241261199. Epub 2024 Jun 16.
3
Monitoring cognitive functioning in MS will trigger anxiety in patients: Yes.
Mult Scler. 2024 Sep;30(10):1252-1254. doi: 10.1177/13524585241261212. Epub 2024 Jun 16.
4
The influence of depression and anxiety on cognition in people with multiple sclerosis: a cross-sectional analysis.
J Neurol. 2024 Aug;271(8):4885-4896. doi: 10.1007/s00415-024-12409-x. Epub 2024 May 11.
5
Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis.
Mult Scler Relat Disord. 2024 Jul;87:105645. doi: 10.1016/j.msard.2024.105645. Epub 2024 May 5.
6
The relationship between depression, anxiety and cognition and its paradoxical impact on falls in multiple sclerosis patients.
Mult Scler Relat Disord. 2018 Oct;25:167-172. doi: 10.1016/j.msard.2018.07.029. Epub 2018 Jul 27.
7
Anxiety in multiple sclerosis is related to depressive symptoms and cognitive complaints.
Acta Neurol Scand. 2020 Mar;141(3):212-218. doi: 10.1111/ane.13191. Epub 2019 Nov 21.
8
Anxiety and Depressive Symptoms Are Associated With Worse Performance on Objective Cognitive Tests in MS.
J Neuropsychiatry Clin Neurosci. 2016 Spring;28(2):118-23. doi: 10.1176/appi.neuropsych.15070167. Epub 2015 Nov 16.
9
The association between executive functioning, coping styles and depressive symptoms in patients with Multiple Sclerosis.
Mult Scler Relat Disord. 2019 Nov;36:101392. doi: 10.1016/j.msard.2019.101392. Epub 2019 Sep 9.
10
Neuropsychological characteristics of benign multiple sclerosis patients: A two-year matched cohort study.
Mult Scler Relat Disord. 2019 Oct;35:150-155. doi: 10.1016/j.msard.2019.07.022. Epub 2019 Jul 27.
引用本文的文献
1
Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosis.
Mult Scler. 2025 Apr;31(5):595-606. doi: 10.1177/13524585251329035. Epub 2025 Apr 1.
本文引用的文献
1
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
Mult Scler. 2022 Jun;28(7):1101-1111. doi: 10.1177/13524585211049397. Epub 2021 Oct 6.
2
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.
Can J Neurol Sci. 2020 Jul;47(4):437-455. doi: 10.1017/cjn.2020.66. Epub 2020 Apr 6.
3
Recommendations for cognitive screening and management in multiple sclerosis care.
Mult Scler. 2018 Nov;24(13):1665-1680. doi: 10.1177/1352458518803785. Epub 2018 Oct 10.
4
Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.
Mult Scler Relat Disord. 2018 Jan;19:153-160. doi: 10.1016/j.msard.2017.11.013. Epub 2017 Nov 21.
5
Characterizing cognitive function during relapse in multiple sclerosis.
Mult Scler. 2014 Nov;20(13):1745-52. doi: 10.1177/1352458514533229. Epub 2014 May 19.
6
Effects of acute relapses on neuropsychological status in multiple sclerosis patients.
J Neurol. 2011 Sep;258(9):1603-8. doi: 10.1007/s00415-011-5975-3. Epub 2011 Mar 8.
7
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.
Mult Scler. 2010 Nov;16(11):1385-92. doi: 10.1177/1352458510378021. Epub 2010 Aug 25.
Zotero 插件